MedTrace Logo

Investigating Ovulation Inhibition for Use as a Contraceptive

NCT07365904 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-26

No results posted yet for this study

Summary

A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch

Conditions

  • Contraception

Interventions

DRUG

MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)

Sponsors & Collaborators

  • Mylan Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Sandeep Jagtap · Meda Pharma GmbH & Co. KG (a Viatris company)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-22
Primary Completion
2026-11-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07365904 on ClinicalTrials.gov